Reactive Oxygen Species (ROS)-Responsive Nanoprobe For Bioimaging And Targeted Therapy of Osteoarthritis

Chong Shen  
Guangxi Medical University  

Ming Gao  
Guangxi Medical University  

Haimin Chen  
Guangxi Medical University  

Yanting Zhan  
Guangxi Medical University  

Qiumei Lan  
Guangxi Medical University  

Zhimin Li  
Guangxi Medical University  

Wei Xiong  
Guangxi Medical University  

Zainen Qin (qn78495036@126.com)  
Guangxi Medical University  

Li Zheng  
Guangxi Medical University  

Jinmin Zhao  
Guangxi Medical University  

---

Research

**Keywords:** ROS-responsive, Drug delivery, Targeted therapy, Osteoarthritis

**DOI:** https://doi.org/10.21203/rs.3.rs-607946/v1

**License:** This work is licensed under a Creative Commons Attribution 4.0 International License.  
Read Full License
Abstract

Stimulus-responsive therapy that allows precise imaging-guided therapy is limited for osteoarthritis (OA) therapy due to the selection of proper physiological markers as stimulus. Based on that the over-production of Reactive Oxygen Species (ROS) is one of the leading causes of OA, we selected ROS as markers and designed a cartilage-targeting and ROS-responsive theranostic nanoprobe that is highly specific for effective bioimaging and therapy of OA. This nanoprobe was fabricated by using PEG micelles modified with ROS-sensitive thiolketal linkers (TK) and cartilage-targeting peptide, termed TKC, which was then encapsulated with Dexamethasone (DEX) to form TKC@DEX nanoparticles. Results showed that the nanoprobe can smartly “turn on” in response to excessive ROS and “turn off” in the normal joint. By applying different doses of ROS inducer and ROS inhibitor, this nanoprobe can emit ROS-dependent fluorescence according to the degree of OA severity, helpful to precise disease classification in clinic. Specifically targeting cartilage, TKC@DEX could effectively respond to ROS and sustained release DEX to remarkably reduce cartilage damage in the OA joints. This smart, sensitive and endogenously activated ROS-responsive nanoprobe is promising for OA theranostics.

Introduction

Osteoarthritis (OA) is a chronic disease characterized by the progressive degeneration of cartilage that leads to joint pain and even serious disabilities of patients around the world[1, 2]. At the end-stage of OA, the joints gradually lose function and need prosthetic replacements surgery[3]. Thus, it is necessary to highlight the diagnosis and treatment of OA at the early-stage.

Nowadays, endogenous-based fluorescent probes relying on certain physiological markers like NO[4] and MMP-13[5–8] to generate fluorescence have been explored for detection of early OA in vivo. However, these probes depending on pathological events are limited in clinical applications mainly due to the relatively low concentrations of endogenous biochemical markers[9–12], resulting in inaccurate and insensitive signals in the deep tissues. Moreover, most probes can only be used for diagnosis/monitoring and have little or no therapeutic effects on OA. Therefore, it is imperative to find remarkable physiological markers and design a responsive theranostic probe that can penetrate through the deep tissues and simultaneously have therapeutic potential for OA.

It is generally accepted that Reactive Oxygen Species (ROS) are important causative factors during the development of OA. It has been reported that the levels of ROS, e.g. H₂O₂, O₂⁻, HO⁻, and HOCl, which maintain at a low level in normal articulatory[13], are dramatically increased (may up to 1 mM) in the joints of OA patients[14]. The over-generation of ROS elicits hyper-peroxidation, protein carbonylation and DNA damage, which has been considered as the main mechanism of cartilage cells loss and tissue damage[15]. But until now, a specific and biocompatible ROS-responsive system has not yet been moved forward to real-time monitoring and therapy of OA.
The drug delivery systems based on ROS-responsive functional moieties such as sulfide[16], phenylboronic acids and esters[17–19], selenium-containing linkage[20], peroxalate[21–23] et., have been widely used for cancer treatment. Among various materials, nano-scaled ROS-responsive polyethylene glycol (PEG) polymers composed of thioketal linkers attracted most intention because of their sensitivity and responsiveness to endogenous ROS down to submicromolar concentrations (~ 100 µM) at deep physiological signaling levels[24–26]. PEG is usually employed to self-assemble micelles due to their excellent biocompatibility, which can shield from the mononuclear phagocyte system (MPS) and prevent host rejection after injected in vivo[27]. Moreover, the PEG micelles of sufficiently small size from 20 to 200 nm facilitates entry into the dense cartilage. Further modification with a targeted biomolecular ligand may resist rapid clearance from the joint site[28, 29]. Thus, the ROS-responsive PEG micelles based on thioketal linkers may hold promise for OA treatment in clinical.

Herein, we developed a multifunctional ROS-activatable theranostic polymer nanoparticles that are capable of loading hydrophobic drug and self-reporting the payload release upon ROS stimulation. The nanoparticles are formed by the amphiphilic block copolymers consisting of Cy5.5 modified cartilage-targeting peptide (CAP, DWRVIIPPRPSA)[30, 31] and PEG modified an oxidation-responsive thioketal linkers (TK) hydrophobic block that contains Black Hole Quencher 3 (BHQ-3) as a quencher for Cy5.5, which was then encapsulated with Dexamethasone (DEX) to form TKC@DEX nanoparticles. DEX is a broad-spectrum synthetic corticosteroid medicine with long-lasting anti-inflammatory effect to potently reduce glycosaminoglycan loss in OA-affected cartilage site[32–34]. As show in Scheme 1, the smart TKC@DEX nanoparticles specifically target on articular cartilage by CAP and respond to the high level of ROS since the thioketal linkages were cleaved by abundant ROS in inflamed tissues, leading to gradual disassembly of the polymer to release Cy5.5 and drug. The increased distance between quencher (BHQ-3) and Cy5.5 enables stronger fluorescence signal from Cy5.5, providing effective diagnosis and monitoring of OA condition. But in normal condition where ROS are minimal, the fluorescence is turned off by BHQ-3. This smart cartilage-targeting ROS responsive theranostic nanoprobe is promising for OA therapy.

**Materials And Methods**

**Synthesis of ROS-responsive polymer**

Here, thioketal were synthesized via their reaction with 3-mercaptopropionic acid and acetone. The fluorescent monomer (Cy5.5-CAP) was synthesized following a route as shown in Figure S1. BHQ-3 was chosen as a quencher and co-polymerized with a ROS-cleavable thioketal-containing linker to prepare the PEG-TK-BHQ-3 (Figure S2-3). The detailed preparation protocols of ROS-responsive polymers are presented in the **Supporting Information** and verified by $^1$H NMR spectra.

**Characterization**

The morphology of TKC-PEG and TKC@DEX was measured by transmission electron microscopy (TEM) (Bruker, Germany). The particle size distribution and zeta potential of the TKC-PEG and TKC@DEX were recorded using a dynamic light scattering (DLS) (Malvern, UK). The DLS was used to investigate the
stability of TKC-PEG incubated in PBS or in different concentrations of KO$_2$ (0 µM, 50 µM and 100 µM) with or without ROS inhibitor (N-acetyl-L-cysteine, NAC) for 0, 1, 2, 4, 8 and 24 h. The Ultraviolet–visible (UV-VIS) absorbance spectra of Cy5.5, BHQ-3 and TKC-PEG were detected by a microplate reader (Thermo Fisher Scientific, USA).

**Fluorescent recovery of TKC-PEG**

The TKC-PEG solution was added to different concentrations of KO$_2$ (0 µM, 50 µM and 100 µM) with or without ROS inhibitor (N-acetyl-L-cysteine, NAC) and then incubated at 37°C for 1, 2, 4, 8 and 24 h, respectively. The fluorescence signals were captured by using *In-vivo* Multispectral Imaging Systems (Bruker, Germany).

**DEX loading**

20 mg of nanoparticles was dispersed in 0.5 mL tetrahydrofuran (THF), followed by the addition of 10 mg DEX (dissolved in 0.5 mL tetrahydrofuran). Then 10 mL deionized water with a syringe was slowly added in to the mixture. The mixture was moved to a dialysis bag (MWCO 3400, Sigma, USA) to dialyze with deionized water for 24 h to remove the unloaded drug. At last, the dried solid micelles were obtained by lyophilization. The drug loading and embedding ratio were measured by the High Performance Liquid Chromatography (HPLC) (Shimadzu, Japan), and then calculated by the following formula using:

Drug loading (%) = weight of DEX entrapped/weight of nanoparticles × 100% (1)

Embedding ratio (%) = weight of DEX entrapped/weight of DEX feeding × 100% (2)

**DEX release study**

The DEX release profiles of TKC@DEX NPs were determined by dialysis membrane method. Briefly, TKC@DEX NPs were placed in dialysis bags and immersed in 15 mL four different buffers: (1) PBS only; (2) PBS with 50 µM KO$_2$; (3) PBS with 50 µM KO$_2$ and its inhibitor; (4) PBS with 100 µM KO$_2$. KO$_2$ was selected as a reagent to simulate the ROS microenvironment[24]. All solutions containing 1% tween 80 were shook constantly at 37°C. At each time point (0, 1, 2, 4, 12 and 24 h), 1 mL of aliquots was removed from the release media and 1 mL of the same buffer was supplemented. The concentration of DEX release from TKC@DEX NPs was measured by HPLC. The procedures were performed in triplicate.

**Chondrocytes isolation and culture**

Chondrocytes were isolated from the knee joints of 3-day-old C57BL6/J mice (the Animal Experimental Center of Guangxi Medical University, Nanning, China) by enzymatic digestion in aseptic conditions according to previous report[35]. Firstly, articular cartilages were digested in trypsin (Gibco, USA) for 40 min at 37°C and then minced and digested with 2 mg/mL collagenase II for 3 h at 37°C. Secondly, the chondrocytes were centrifuged at 1000 rpm for 5 min and then suspended in DMEM medium containing 10% fetal bovine serum (FBS, Gibco, USA), 1% penicillin and streptomycin (Solarbio, China). Then, they
were transferred into a culture flask and cultured at 37°C in a 5% CO₂-humidified incubator. The third generation of cells was collected for further experiments.

**In vitro cytotoxicity assay**

The cytotoxicity of TKC-PEG and TKC@DEX in chondrocytes was determined by Cell Counting Kit-8 (CCK-8, Japan). Briefly, cells were incubated in medium containing various concentrations of TKC-PEG (0, 3, 6, 12, 25, 50, 100, 200 µg/mL) or TKC@DEX (0, 3, 6, 12, 25, 50, 100, 200 µg/mL) for 24 and 48 h. Afterward, each well was added with 10 µL CCK-8 and incubated for 4 h in humidified incubator. The absorbance of solutions was detected at a wavelength of 450 nm by a microplate reader (Thermo Fisher Scientific, USA). CCK-8 assay was also used to assess the cell viability of MIA-induced chondrocytes after treatment with DEX, CAP@DEX, TK@DEX, or TKC@DEX for 24 h.

**Hemolysis test**

The hemolysis ratio of TKC@DEX at various concentrations (50, 100, 200, 400, 800 µg/mL) was performed *in vitro* [36]. The TKC@DEX samples were dissolved in PBS at 37°C. Then 20.0 µL of erythrocyte dispersion was added into the TKC@DEX solution (1.0 mL) and the mixture was incubated for 1 h at 37 °C. After centrifuged at 2000 rpm for 10 min, the hemoglobin in supernatant was measured using a microplate reader at 415 nm. The positive and negative controls were determined by replacing the sample solution with ultrapure water and PBS, respectively. Experiments were performed for three times and the hemolysis rate (%) was calculated using following equation: \( \frac{A_s - A_n}{A_p - A_n} \times 100 \), where \( A_s \), \( A_n \), and \( A_p \) mean absorbencies of the sample, negative control and positive control, respectively.

**Intracellular ROS detection and bioimaging**

We used monosodium iodoacetate (MIA), an inhibitor of glyceraldehyde-3-phosphate dehydrogenase activity, to induce oxidative stress injury and the pathological OA symptoms of chondrocytes [37]. Chondrocytes were seeded into 6-well or 24-well plates and divided into four groups: (1) control: chondrocytes cultured with medium only; (2) MIA 3 µM: chondrocytes induced with 3 µM MIA for 24 h; (3) MIA + inhibitor: chondrocytes pretreated with 5 mM NAC [38] (N-acetylcysteine, the antioxidant which can significantly prevent the production of ROS) for 1 h followed by addition with 3 µM MIA for 24 h; (4) MIA 6 µM: chondrocytes induced with 6 µM MIA for 24 h. Intracellular ROS production was determined by using a fluorescent 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA) kit. Chondrocytes were harvested, and incubated with DCFH-DA (10 µM) for 20 min in the dark at 37°C. The chondrocytes were then washed three times with serum-free medium, and immediately detected by flow cytometer (BD, Biosciences, USA) [39]. The ROS generation of normal chondrocytes was also measured. Meanwhile, to reduce the production of ROS induced by MIA, chondrocytes were pretreated with 5 mM NAC for 1 h, follow by the addition of 3 µM MIA for 24 h, then intracellular ROS was detected.

In addition, cellular uptake and degradation of TKC-PEG NPs induced by endogenous ROS were investigated. After treated with MIA, the chondrocytes were incubated with TKC-PEG NPs for 4 h, and then
they were washed with PBS and fixed with 95% ethanol for 30 min. Meanwhile, MIA (3 \mu M) treated cells were also incubated with CAP-PEG and TK-PEG NPs as controls. Then the chondrocytes were stained with immunofluorescence of COL2A1 (1:200, Boster) and nuclei was counterstained with DAPI. Finally, the fluorescence images were photographed using a fluorescence inversion microscope (OLYMPUS, Japan).

**MIA-induced chondrocytes and treatment**

Chondrocytes were seeded into 24-well or 6-well plates and separated into five groups: (1) control: chondrocytes cultured with medium only; (2) MIA: chondrocytes induced with 3 \mu M MIA; (3) MIA + DEX: chondrocytes pretreated with 3 \mu g/mL DEX for 1 h followed by addition with 3 \mu M MIA for 24 h; (4) MIA + TK@DEX: chondrocytes pretreated with TK@DEX (an equivalent DEX dose of 3 \mu g/mL) for 1 h followed by addition with 3 \mu M MIA for 24 h; (5) MIA + CAP@DEX: chondrocytes pretreated with CAP@DEX (an equivalent DEX dose of 3 \mu g/mL) for 1 h followed by addition with 3 \mu M MIA for 24 h; (6) MIA + TKC@DEX: chondrocytes pretreated with TKC@DEX (an equivalent DEX dose of 3 \mu g/mL) for 1 h followed by addition with 3 \mu M MIA for 24 h.

**Quantitative real-time polymerase chain reaction (RT-qPCR) analysis**

The primer sequences for the OA-related genes are listed in Table 1. Total RNA was isolated using an RNA isolation kit (Tiangen Biotechnology, China). Then a reverse transcription kit (Takara, Japan) was used to reversely transcribe RNA to cDNA. Real-time PCR was conducted by a Light Cycle 96 system for 10 min at 95°C, 15 s at 95°C, and 60 s at 60°C. The relative gene expression levels were calculated using the \(2^{-\Delta \Delta CT}\) method with \(\beta\)-actin as the control.

**Immunofluorescence.**

The expression of OA catabolic biomarkers IL-6 and MMP-13 in chondrocytes was assessed by immunofluorescence. Chondrocytes were fixed with 95% ethanol for 30 min and permeabilized with 0.1% Triton X-100 for 10 min. Samples were incubated with primary antibody as follows: IL-6 (1:200, Boster, China), and MMP-13 (1:200, Boster) at 4°C overnight. Then the samples treated with the secondary antibodies FITC-anti-rabbit IgG (1:50, Boster) for 60 min at 37°C and counterstained with DAPI for 5 min. Finally, the fluorescence images were photographed using a fluorescence inversion microscope (OLYMPUS, Japan).

**OA model and treatment.**

All animal experiments were approved by the Ethics Committee of Guangxi Medical University. A total of 60 C57BL6/J (8 weeks old, male) were obtained for this experiment. To induce OA, mice received a single IA injection of 0.05 or 0.1 mg of MIA (Sigma, USA) after anesthesia[40–42]. After induction of OA model, the mice were randomly sorted into five groups (n = 6): PBS group, IA injections of 50 \mu L PBS; DEX group, IA injections of 50 \mu L PBS with DEX (1 mg/kg); CAP@DEX group, IA injections of 50 \mu L PBS with CAP@DEX (an equivalent DEX dose of 1 mg/kg); TK@DEX group, IA injections of 50 \mu L PBS with
TK@DEX (an equivalent DEX dose of 1 mg/kg) and TKC@DEX group (an equivalent DEX dose of 1 mg/kg). IA injections were performed twice a week. The rats in these groups were sacrificed for further analysis at 2 and 4 weeks after therapy.

**In vivo NIR bioimaging**

For *in vivo* bioimaging, mice were anesthetized by isoflurane. Each group of OA mice (n = 6) was IA injected with 50 µL of 400 µg/mL TKC-PEG, CAP-PEG or TK-PEG, and the normal mice (n = 6) were also IA injected with TKC as control. The images were captured by an *In-vivo* Multispectral Imaging Systems (Bruker, Germany) at 0, 1, 2, 4, 7 and 14 d.

In addition, the fluorescence intensity of the TKC was also investigated. The mice were randomly sorted into three groups (n = 6): 0.05 mg MIA + inhibitor group, IA injection of 0.05 mg MIA concomitant with 5 mM NAC; 0.05 mg MIA group, IA injection of 0.05 mg MIA; 0.1 mg MIA group, IA injection of 0.1 mg MIA[43, 44]. Finally, the mice were sacrificed and the macroscopic evaluations of joints were performed.

**Macroscopic observation**

After 2 weeks or 4 weeks of treatment, the knee joints of mice were harvested for macroscopic evaluation according to the macroscopic scoring system (scale of 0–4) by three independent observers[45].

**Histological analysis.**

The joints were fixed in 4% paraformaldehyde and subsequently decalcified with a 14% ethylenediaminetetraacetic acid (EDTA) solution for ten days. Next the joints were embedded in paraffin and cut into 5 µm thick slices by sharp blade. HE (Solarbio, China) and safranin O-fast green (Solarbio, China) staining were performed for histomorphological analysis. The severities of OA were graded by three independent observers by using the Osteoarthritis Research Society International (OARSI) score (scale of 0–24)[46]. Furthermore, Immunohistochemical staining for MMP13 (1:200, Boster) was performed to evaluate the anti-inflammatory effects of the probes.

**Statistical Analysis.**

All data are presented as the mean ± SD, and p < 0.05 was considered statistically significant. The significant differences among groups were evaluated by one-way ANOVA. Statistical analyses were conducted using SPSS statistics (SPSS 19.0).

**Results**

**Synthesis and Fabrication of nanoreactors**

The successful synthesis of ROS responsive monomer and functional moiety were demonstrated by $^1$HNMR spectra *(Figure S1-S5)*. The transmission electron micrograph (TEM) showed that the amphiphilic
polymer TKC-PEG and TKC@DEX could self-assemble into homogeneously spherical nanoparticles in aqueous solution (Fig. 1a&b). Furthermore, dynamic light scattering (DLS) analysis revealed that the average diameter of TKC-PEG NPs was ~ 60 nm (Fig. 1c). The zeta potential of TKC-PEG NPs was close to neutral charges at -0.13 mV (Fig. 1d). After loading with DEX, the mean diameter of TKC@DEX NPs increased up to ~90 nm (Fig. 1b&1c) and the zeta potential changed to -0.43 mV (Fig. 1d). The UV-vis spectrum also confirmed the successful construction of TKC-PEG. As shown in Fig. 1e, characteristic peaks of Cy5.5 in Cy5.5-CAP-PEG-TK (TKC-PEG) (red line) and BHQ-3 (blue line) were demonstrated. There is a red shift induced by BHQ-3 in TKC-PEG, which is synthesized by Cy5.5-CAP-PEG-TK (TKC-PEG) and BHQ-3 through acyl chloride. It showed a decreased fluorescence intensity of TKC-PEG compared with Cy5.5-CAP-PEG-TK (TKC-PEG) due to the link of BHQ-3. To confirm the ROS-responsive fluorescence activation properties, different concentrations of KO₂ were added to the TKC-PEG NPs and their fluorescence intensity was monitored. In the absence of KO₂, the fluorescence of TKC-PEG was extremely weak over time due to the short distance between Cy5.5 and BHQ-3 (Fig. 1f&1g). However, when KO₂ (50 µM) was added, the TKC-PEG showed gradual recovering of NIR fluorescence over incubation time due to that the ROS cleaved the thiokeatal of TKC-PEG and increased the distance between Cy5.5 and BHQ-3. The recovery of fluorescence intensity was effectively accelerated with the increasing concentration of KO₂ from 50 µM to 100 µM, but it was suppressed when an ROS inhibitor NAC was added together with the KO₂. The TKC-PEG NPs had good stability in PBS, showing no appreciable change in size distribution. On the contrary, the size rapidly increased under different concentration of KO₂ (50 µM and 100 µM) as the inducer of ROS, suggesting that the disassembly of TKC-PEG NPs was triggered in response to oxidative milieu (Fig. 1h).

**In vitro drug release at ROS-simulated levels**

As confirmed by the results of in vitro fluorescent recovery study (Fig. 1g), the high level of ROS in OA intracellular could break thiokeetal linkers and also trigger the release of DEX. The drug loading and embedding ratio were 13% and 30% for the TKC-PEG NPs, respectively. The in vitro drug release showed that only 19% drug was released in the absence of KO₂ (ROS inducer) after incubation for 48 h (Fig. 1i). The drug release reached up to 42% and 58% after treatment with 50 µM and 100 µM KO₂ for 48 h, respectively, indicating obviously accelerated DEX release from the TKC@DEX NPs by KO₂ in a dose-dependent manner. The drug release could be inhibited by the ROS inhibitor NAC (only 26% of DEX release), because NAC could significantly prevent the production of ROS and the degradation of thiokeetal linkers. All these results confirmed that DEX released slowly in PBS, showing no notable change without KO₂. On the contrary, DEX rapidly increased in the presence of KO₂, suggesting that the disassembly of TKC NPs was triggered by ROS according to the concentration of KO₂.

**Cytotoxicity analysis**

The cytotoxicity of TKC-PEG and TKC@DEX NPs on chondrocytes was evaluated by CCK-8 assay. As show in Fig. 2a, no toxicity was observed with DEX at the range of 0 to 200 µg/mL after 24 h and 48 h incubation. After DEX loading, 25 µg/mL TKC@DEX (equivalent concentration of DEX was 3 µg/mL)
promoted cell growth compared with untreated chondrocytes (Fig. 2b). Thus, 25 μg/mL TKC@DEX was selected for further study.

The effect of TKC@DEX on the cell viability of MIA (ROS inducer)-induced chondrocytes[47] was investigated by CCK-8 analysis. As shown in Fig. 2c, the cell viability of the chondrocytes treated with MIA decreased 40.7% compared with the normal cells. However, after treating with DEX, CAP@DEX, TK@DEX and TKC@DEX for 24 h, the cell viability was increased to 70.27%, 74.14%, 78.78% and 87.97% compared with the MIA group, respectively, suggesting potential function of protecting chondrocytes from catabolic activity of inflammatory factor and promoting chondrocytes proliferation.

Hemolysis test

The biocompatibility of TKC@DEX was measured by the hemolysis test. As shown in Figure 2d, the TKC@DEX at various concentrations induced lower than 4.0% hemolysis rate by contacting erythrocytes at 37°C for 1 h. These results indicated that TKC@DEX NPs were considered as excellent biocompatible and nonhemolytic materials, showing a great potential of biomaterials for clinical applications.

Cell uptake and in situ fluorescent release

To investigate the chondrocytes targeting property of TKC-PEG NPs, cellular uptake of TKC-PEG and TK-PEG (without chondrocyte-affinity CAP peptide) NPs were compared. Treatment with 3 μM and 6 μM MIA caused a 1.1-fold and 2.7-fold increase of red fluorescence (46.40% and 82.51%) in the cellular uptake compared with untreated cells (22.19%), respectively (Figure 2e&2f), which revealed that thio-ketal linkages exhibited efficient ROS-dependent degradation. The fluorescence intensity of TKC-PEG group was observed to be much stronger than that of TK-PEG group after treatment with 3 μM MIA (Figure 2e&2g). However, the fluorescence intensity declined to 30.55% after treating with NAC, which was similar to that of normal cell environment due to the elimination of ROS (Figure 2e&2f). These results indicated that ROS could trigger the cleavage of thio-ketal linkages to release Cy5.5 from TKC-PEG according to the level of ROS at simulated pathological conditions, and the targeting effect of CAP moieties in TKC-PEG NPs could facilitate high affinity to CEM-rich chondrocytes compared those with non-targeting modality. But in normal condition, Cy5.5 was hardly released and activated. The flow cytometer was used to monitor the ROS production in chondrocytes (Figure 2h). At OA microenvironment induced by MIA (the concentration was 3 μM), an elevated level of ROS (24.10%) was produced compared with normal cells (12.75%). And the ROS was up to 42.76% at the concentration of 6 μM MIA, indicating a significant increase of ROS production dependent on the concentration of MIA. Furthermore, the high level of ROS could decrease down to 17.48% after treated with NAC. Thus TKC-PEG may potentiate smart real-time monitoring of ROS levels.

In vitro anti-inflammatory activity

We then evaluated the efficacy of treatment groups to induce crucial OA catabolic biomarkers (MMP13, IL-6, and MMP-3) and chondrogenic markers genes (Col2a1) by qRT-PCR (Fig. 3a). It showed that the
MMP13, IL-6 and MMP-3 expression of TKC@DEX group was significantly decreased than that of the MIA-treated group, down to 80.85%, 91.30% and 64.19%, respectively. Compared with DEX, CAP@DEX and TK@DEX group, there were 56%, 36% and 18% decreases of MMP13, IL-6 and MMP-3 expression in TKC@DEX group respectively, indicating its pronounced anti-inflammatory effect. TKC@DEX group also significantly up-regulated the expression of Col2a1, one key component of the cartilage matrix compared with other groups after 24 h of culture (Fig. 3a), suggesting that TKC@DEX NPs inhibited the degradation of collagen and protected chondrocytes under the pathological conditions of OA. The expression of OA biomarkers by immunofluorescent staining further confirmed the PCR results (Fig. 3b&3c). The results showed the expressions of MMP-13 and IL-6 were both decreased in the TKC@DEX group, almost 25%~45% lower than other groups (MIA, DEX, CAP@DEX and TK@DEX groups).

In vivo ROS-responsive activity

We then evaluated the efficacy of treatment groups to induce crucial OA catabolic biomarkers (MMP13, IL-6, and MMP-3) and chondrogenic markers genes (Col2a1) by qRT-PCR (Figure 3a). It showed that the MMP13, IL-6 and MMP-3 expression of TKC@DEX group was significantly decreased than that of the MIA-treated group, down to 80.85%, 91.30% and 64.19%, respectively. Compared with DEX, CAP@DEX and TK@DEX group, there were 56%, 36% and 18% decreases of MMP13, IL-6 and MMP-3 expression in TKC@DEX group respectively, indicating its pronounced anti-inflammatory effect. TKC@DEX group also significantly up-regulated the expression of Col2a1, one key component of the cartilage matrix compared with other groups after 24 h of culture (Figure 3a), suggesting that TKC@DEX NPs inhibited the degradation of collagen and protected chondrocytes under the pathological conditions of OA. The expression of OA biomarkers by immunofluorescent staining further confirmed the PCR results (Figure 3b&3c). The results showed the expressions of MMP-13 and IL-6 were both decreased in the TKC@DEX group, almost 25%~45% lower than other groups (MIA, DEX, CAP@DEX and TK@DEX groups).

In vivo ROS-responsive activity

To detect the ROS activity at the early stage of OA, we established the OA model by IA injection of MIA (ROS inducer). In the normal group (healthy joints) treatment, IA injection of TKC-PEG probes resulted in weak fluorescent signal in the normal group (healthy joints) and the relative fluorescence intensity was 1.20 at 1 day (Fig. 4a&4b). By contrast, a strong fluorescent signal was detected in the OA joints, indicating significantly up-regulated ROS activity in the OA joints compared to healthy joints. The relative fluorescence intensity of TKC-PEG group in OA sites reached peak intensity at 1 d, and still maintained obvious fluorescence at 14 d. Moreover, the relative fluorescence intensity of TKC-PEG NPs treated mice was nearly ~ 1.34-fold higher than that of CAP-PEG NPs, and ~ 0.98-fold higher than TK NPs (Fig. 4a&4b) at 7d, indicating that the decoration of CAP-PEG endowed the potential enrichment effect of TKC-PEG NPs and thiketal linkage could be effectively cut off by ROS in cartilage. Thus, TKC-PEG NPs exhibited cartilage targeting property and prolonged retention time in joints, which was suitable for effective bioimaging to detect the development of OA in vivo.
Compared with the OA mice (0.05 mg MIA) injected with the TKC-PEG probes, those injected with the TKC-PEG + ROS inhibitor group produced undetectable fluorescence signal (Fig. 4c&4d). In addition, when mice injected with 0.1 mg MIA, a higher ROS circumstance was induced, leading to more serious joint damage (Fig. 4c&4d). And the relative fluorescence intensities could be increased at higher ROS circumstance (IA with 0.1 mg MIA), increasing up to 30% higher than that of IA with 0.05 mg MIA after treated with TKC-PEG probes. This result indicated that the intensity of fluorescent signals of TKC-PEG probe could respond to ROS related OA severity, favorable for precise disease classification.

**In vivo treatment effect**

We further carried out in vivo experiments to evaluate the OA therapeutic efficacy of TKC@DEX. The mice were divided into six groups, including PBS, OA, DEX, CAP@DEX, TK@DEX and TKC@DEX. In the PBS-treated group, general characteristic OA features, such as surface irregular and large cartilage erosion, were observed. The macroscopic score of OA group was significantly higher than that of control group over time, which indicated mild or moderate cartilage destruction based on pathological alteration of joint morphology from 2 to 4 weeks (Fig. 5a). After treatment with DEX, there was a 31.82% and 30.67% reduction in the joint score in 2 weeks and 4 weeks, respectively, as compared to that of treatment with PBS alone. Meanwhile, both CAP@DEX and TK@DEX treatment significantly decreased the severity of OA. Furthermore, there was a 64.55% and 57.87% reduction in TKC@DEX group after treatment for 2 and 4 weeks, respectively, compared to that OA group, which showed its effective therapeutic repair effect of OA (Fig. 5b).

The HE and safranin O/fast green staining were used to evaluate the therapy efficacy of TKC@DEX in vivo (Fig. 6a&6b). In the OA group, OA characteristics, including cartilage damage, fibrillated lesions and loss of aggrecan worsened over time, were showed in the progression of OA. In contrast, TKC@DEX treatment resulted in a significant improvement in matrix arrangement, tide line maintenance or cartilage lesion, and the OARSI score exhibited improvement, with a reduce of 86.7% and 86% compared with OA group at 2 and 4 weeks, respectively (Fig. 6c). The scores for the TKC@DEX group were markedly lower than that of other treatment groups, exhibiting positive effects on the restoration of cartilage matrix expression.

We also assessed the expression of MMP-13 in OA cartilage by immunohistochemistical analysis, which is a degradation product of type II collagen and corresponds to articular cartilage damage in the early stages of OA. The positive staining of MMP-13 could hardly be detected in the normal cartilage. In contrast, it showed high expression in the superficial and middle zones of the cartilage in OA group. Following treatment with DEX, CAP@DEX or TK@DEX, osteoarthritic changes of MMP-13 over-expression was reduced (Fig. 6d). These results indicated that TKC@DEX significantly slowed the progression of early OA and prevented the severe damage to articular cartilage in the OA.

**Discussion**
The abnormal over-production of endogenous ROS within cartilage tissue is a key hallmark of OA[48], providing a disease-specific triggering mechanism for drug control and release systems. Herein, we fabricated an advance ROS responsive and cartilage targeting TKC@DEX nanoprobe with loaded drug for imaging and effective therapy of OA, which may provide reference for clinical application.

As a promising domain, ROS-stimuli responsive theranostic nanoprobes have been widely applied in disease theranostic owing to their unique all-in-one features[49–51]. Chung et al. proposed ultrasensitive ROS-responsive carriers that contained agents to release the drug to the disease site[48, 52, 53]. Compared with unresponsive delivery systems, these ROS-responsive systems remain stable in normal tissue, preventing their release to non-inflamed tissues, which suggested their specificity in inflammation site. But these ROS responsive nano systems can only control the release of drugs, but cannot visually real-time monitor the progression of disease and most of them have no therapeutic effect. In our study, TKC@DEX is superior to unresponsive CAP@DEX, as evidenced by fluorescent recovery studies simulated by abundant of ROS in vitro and vivo (Fig. 1f, 1g, 2e&4a). The fluorescent signal is strong in the OA microenvironment, but is extremely weak in normal chondrocytes and joints, indicating that the level of fluorescence signal correlates with ROS content. TKC@DEX not only exhibits smart drug release potential in response to high levels of ROS as demonstrated by drug release behavior test (Fig. 1i), but also can real-time track ROS activity since it emits signal of fluorescence varied with ROS, promising for monitoring and on-demand therapy of OA.

On the other hand, cartilage targeting is of importance for drug therapy. Most in situ injected particles may be quickly cleared by the joint fluid because of the inability of homing to lesion sites, leading to application limitations in OA diagnosis and treatment. Liu et al. engineered a chondrocyte-affinity peptide (CAP, DWRVIIPPRPSA)[31, 54, 55] by phage display technology. In our study, the nanoprobe TKC with cartilage targeting CAP showed stronger fluorescence than TK (without CAP), as observed in vitro cellular uptake tests (Fig. 2a) and in vivo NIR imaging (Fig. 4). Moreover, the CAP-modified TKC@DEX prolonged the retention time of nanoparticles in the joint (Fig. 4a&4c), which could improve therapeutic outcomes of OA. These results indicated that cartilage targeting ensured the real-time monitoring and specific treatment of OA.

In our studies, we observed that the TKC@DEX NPs showed stronger therapeutic efficacy than that of delivery systems without conjugation of CAP and TK. The TKC@DEX NPs play a key role in relieving the inflammation in vitro and in vivo (Fig. 3a, 3b, 3c&Figure 5). The results of macroscopic and histological analysis further evaluated that IA injection of TKC@DEX showed the better therapeutic effect than other formulations (TK@DEX, CAP@DEX or free DEX) after 2 and 4 weeks of treatment (Fig. 5–6). In addition, hemolysis test further assessed the excellent biocompatibility of the TKC@DEX NPs platform (Fig. 2d). The above results revealed that the drug delivery system targeted to the cartilage and responded well to low concentrations of ROS, exhibiting highly sensitive imaging and effective anti-inflammatory activity for therapy of OA.

Conclusions
In summary, we have successfully fabricated a novel cartilage-targeting and ROS-responsive delivery platform for diagnosis and therapy of OA, which enables real-time imaging to monitor the severity of OA and on-demand drug release at the site of abnormal ROS milieu. We expect that this theranostic system may be applied in clinic for treatment of OA.

Declarations

Supporting Information

All data generated or analysed during this study are included in this published article and its supplementary information files.

Acknowledgements

We really appreciated for their kindly help with the In-vivo optical imaging by the Center for Translational Medicine of Guangxi Medical University (Nanning, China).

Authors’ contributions

CS, MG, HMC, ZNQ and LZ designed experiments and wrote the manuscript. CS, MG, and HMC synthesized and analyzed the nanodrugs. CS, MG, and HMC conducted the \textit{vitro} and \textit{vivo} experiments. CS, MG and HMC conducted the \textit{in vivo} optical imaging and analysis the results. JMZ and LZ provided the fund for this research. QML, ZML and WX helped to edited the figures. YTZ performed statistical analysis of the data. All authors read and approved the final manuscript.

Acknowledgments

This study was financially supported by National Natural Science Fundation of China (Grant No.81960414), the Guangxi Key Research and Development Plan (Grant No. GuikeAD19254003), the Guangxi Science and Technology Base and Talent Special Project (Grant No. GuikeAD17129012), the Guangxi Science and Technology Major Project (Grant No. GuikeAA19254002).

Ethics approval and consent to participate

Animal care conformed to institutional guidelines. All animal studies were agreed by the Institutional Ethics Committee of Guangxi Medical University

Consent for publication

All authors agree to be published

Competing interests

No potential conflicts of interest were disclosed.
References

1. Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, Bridgett L, Williams S, Guillemin F, Hill CL, 
   Laslett LL, Jones G, Cicuttini F, Osborne R, Vos T, Buchbinder R, Woolf A, March L. The global burden 
   of hip and knee osteoarthritis: estimates from the global burden. Ann Rheum Dis. 2014;73:1323–30.

2. Holt HL, Katz JN, Reichmann WM, Gerlovin H, Wright EA, Hunter DJ, Jordan JM, Kessler CL, Losina E. 
   Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60–64 
   year-old US adults. Osteoarthritis Cartilage. 2011;19:44–50.

3. Bijlsma JWJ, Berenbaum F, Floris PJG, Lafeber FPJG. Osteoarthritis: an update with relevance for 
   clinical practice. Lancet. 2011;377:2115–26.

4. Jin P, Wiraja C, Zhao JM, Zhang JL, Zheng L, Chenjie Xu CJ. Nitric Oxide Nanosensors for Predicting 
   the Development of Osteoarthritis in Rat. ACS Appl Mater Interfaces. 2017;9:25128–37.

5. Lee S, Park K, Lee SY, Ryu JH, Park JW, Ahn HJ, Kwon IC, Youn IC, Kim K, Choi K. Dark quenched 
   matrix metalloproteinase fluorogenic probe for imaging osteoarthritis. Bioconjug Chem. 
   2008;19:1743–7.

6. Castano AD, Lim NH, Tranchant I, Amoura M, Beau F, Wieland H, Kingler O, Herrmann M, Nazaré M, 
   Plettenburg O, Dive V, Vicent MJ, Nagase H. In Vivo Imaging of MMP-13 Activity Using a Specific 
   Polymer-FRET Peptide Conjugate Detects Early Osteoarthritis and Inhibitor Efficacy. Adv Funct Mater. 
   2018;28:37.

7. Lim NH, Meinjohanns E, Meldal M, Gharios GB, Nagase H. In vivo imaging of MMP-13 activity in the 
   murine destabilised medial meniscus. Osteoarthritis Cartilage. 2014;22:862–8.

8. Ryu JH, Lee A, Lee S, Ahn CH, Park JW, Leary JF, Sangjin Park K, Kim, Ick Chan Kwon, I-C, Youn K, 
   Choi, "One-step" detection of matrix metalloproteinase activity using a fluorogenic peptide probe-
   immobilized diagnostic kit. Bioconjug Chem. 2010;21:1378-84.

9. Bellucci F, Meini S, Cucchi P, Catalani C, Nizzardo A, Riva A, Guidelli GM, Ferrata P, Fioravanti A, Maggi 
   CA. Synovial uid levels of bradykinin correlate with biochemical markers for cartilage. Osteoarthritis 
   Cartilage. 2013;21:1774–80.

10. Karan A, Karan MA, Vural P, Erten N, Taşcioğlu C, Aksoy C, Canbaz M, Oncel A. Synovial uid nitric 
    oxide levels in patients with knee osteoarthritis. Clin Rheumatol. 2003;22(6):397–9.

11. Maher MC, Schnabel LV, Cross JA, Papich MG, Divers TJ, Fortier LA. Plasma and synovial uid 
    concentration of doxycycline following low-dose, low-frequency administration, and resultant 
    inhibition of matrix metalloproteinase-13 from interleukin-stimulated equine synoviocytes. Equine 
    Vet J. 2014;46:198–202.

12. Beekman B, El BV, Drijfhout JW, Ronday HK, TeKoppele JM. Highly increased levels of active 
    stromelysin in rheumatoid synovial uid determined by a selective fluorogenic assay. FEBS Lett. 
    1997;418:305–9.

13. Lepetsos P, Papavassiliou AG. ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys 
    Acta. 2016;1862:576–91.
14. Andersen NS, Cadahía JP, Previtali V, Bondebjerg J, Hansen CA, Hansen AE, Andresen TL, Clausen MH. Methotrexate prodrugs sensitive to reactive oxygen species for the improved treatment of rheumatoid arthritis. Eur J Med Chem. 2018;156:738–46.

15. Hosseinzadeh A, Kamrava SK, Joghataei MT, Darabi R, Zadeh AS, Shahriari M, Reiter RJ, Ghaznavi H, Mehrzadi S. Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 2016;61:411–25.

16. Yuan YY, Liu J, Liu B. Conjugated-polyelectrolyte-based polyprodrug: targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon irradiation with a single light source. Angew Chem Int Ed Engl. 2014;53:7163–8.

17. Lee S, Stubelius A, Hamelmann N, Tran V, Almutairi A. Inflammation-Responsive Drug-Conjugated Dextran Nanoparticles Enhance Anti-Inflammatory Drug Efficacy. ACS Appl Mater Interfaces. 2018;10:40378–87.

18. Kim EJ, Bhuniya S, Lee H, Kim HM, Cheong C, Maiti S, Hong KS, Kim JS. An activatable prodrug for the treatment of metastatic tumors. J Am Chem Soc. 2014;136:13888–94.

19. Lv W, Xu JP, Wang XQ, Li XR, Xu QW, Xin HL. Bioengineered Boronic Ester Modified Dextran Polymer Nanoparticles as Reactive Oxygen Species Responsive Nanocarrier for Ischemic Stroke Treatment. ACS Nano. 2018;12:5417–26.

20. Yang B, Wang KY, Zhang D, Sun BJ, Ji B, Wei L, Li ZB, Wang ML, Zhang XB, Zhang HT, Kan QM, Luo C, Wang YJ, He ZG, Sun J. Light-activatable dual-source ROS-responsive prodrug nanoparticle for synergistic chemo-photodynamic therapy. Biomater Sci. 2018;6:2965–75.

21. Jung E, Noh JY, Kang CS, Yoo D, Song C, Lee D. Ultrasound imaging and on-demand therapy of peripheral arterial diseases using H₂O₂-Activated bubble generating anti-inflammatory polymer particles. Biomaterials. 2018;179:175–85.

22. Kang CS, Cho W, Park M, Kim J, Park S, Shin D, Song C, Lee D. H₂O₂-triggered bubble generating antioxidant polymeric nanoparticles as ischemia/reperfusion targeted nanotheranostics. Biomaterials. 2016;85:195–203.

23. Kim S, Park H, Song Y, Hong D, Kim O, Jo E, Khang G, Lee D. Reduction of oxidative stress by p-hydroxybenzyl alcohol-containing biodegradable polyoxalate nanoparticulate antioxidant. Biomaterials. 2011;32:3021–9.

24. Xu XD, Saw PE, Tao W, Li YJ, Ji XY, Bhasin S, Liu YL, Ayyash D, Rasmussen J, Huo M, Shi JJ, Farokhzad OC. ROS-Responsive Polyprodrug Nanoparticles for Triggered Drug Delivery and Effective Cancer Therapy. Adv Mater. 2017;29:201700141.

25. Zhang WJ, Hu XL, Shen Q, Xing D. Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy. Nat Commun. 2019;10:1704.

26. Cheng DB, Zhang XH, Yu-Juan Gao YJ, Ji L, Hou DY, Wang ZQ, Xu WH, Qiao ZY, Wang H. Endogenous Reactive Oxygen Species-Triggered Morphology Transformation for Enhanced Cooperative Interaction with Mitochondria. J Am Chem Soc. 2019;141:7235–9.
27. Kavanaugh TE, Werfel TA, Cho H, Hasty KA, Duvall CL. Particle-based technologies for osteoarthritis detection and therapy. Drug Deliv Transl Res. 2016;6:132–47.
28. Rothenfluh DA, Bermudez H, O’Neil CP, Hubbell JA. Biofunctional polymer nanoparticles for intra-articular targeting and retention in cartilage. Nat Mater. 2008;7:248–54.
29. Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev. 2013;65:71–9.
30. Ouyang ZX, Tan TT, Liu CF, Duan J, Wang WC, Guo XN, Zhang Q, Li ZL, Huang QL, Dou PC, Liu T. Targeted delivery of hesperetin to cartilage attenuates osteoarthritis by bimodal imaging with Gd 2(CO 3) 3@PDA nanoparticles via TLR-2/NF-κB/Akt signaling. Biomaterials. 2019;205:50–63.
31. Pi YB, Zhang X, Shi JJ, Zhu JX, Chen WQ, Zhang CG, Gao WW, Zhou CY, Ao YF. Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display. Biomaterials. 2011;32:6324–32.
32. Lu YHCS, Evans CH, Grodzinsky AJ. Effects of short-term glucocorticoid treatment on changes in cartilage matrix degradation and chondrocyte gene expression induced by mechanical injury and inflammatory cytokines. Arthritis Res Ther. 2011;13:R142.
33. Asadullah K, Schäcke H, Cato ACB. Dichotomy of glucocorticoid action in the immune system. Trends Immunol. 2002;23:120–2.
34. Huebner KD, Shrive NG, Frank CB. Dexamethasone inhibits inflammation and cartilage damage in a new model of post-traumatic osteoarthritis. J Orthop Res. 2014;32:566–72.
35. Rao ZT, Wang SQ, Wang JQ. Peroxiredoxin 4 inhibits IL-1β-induced chondrocyte apoptosis via PI3K/AKT signaling. Biomed Pharmacother. 2017;90:414–20.
36. Santos MV, Rocha LB, Vieira EG, Oliveira AL, Lobo AO, Carvalho MA, Osajima JA, Silva-Filho EC. Development of Composite Scaffolds Based on Cerium Doped-Hydroxyapatite and Natural Gums-Biological and Mechanical Properties. Materials (Basel). 2019;12:2389.
37. Jiang LP, Li LJ, Geng CY, Gong DZ, Jiang LJ, Ishikawa N, Kajima K, Zhong LF. Monosodium iodoacetate induces apoptosis via the mitochondrial pathway involving ROS production and caspase activation in rat chondrocytes in vitro. J Orthop Res. 2013;31:364–9.
38. Morita K, Miyamoto T, Fujita N, Kubota Y, Ito K, Takubo K, Miyamoto K, Ninomiya K, Suzuki T, Iwasaki R, Yagi M, Takaishi H, Toyama Y, Suda T. Reactive oxygen species induce chondrocyte hypertrophy in endochondral ossification. J Exp Med. 2007;204:1613–23.
39. Park C, Jeong JW, Lee DS, Yim MJ, Lee JM, Han MH, Kim S, Kim HS, Kim GY, Park EK, You- Jeon J, Cha HJ, Choi HY. Sargassum serratifolium Extract Attenuates Interleukin-1β-Induced Oxidative Stress and Inflammatory Response in Chondrocytes by Suppressing the Activation of NF-κB, p38 MAPK, and PI3K/Akt. Int J Mol Sci. 2018;19:2308.
40. Uchimura T, Nakamura DS, Link EM, Noguchi Y, Ōmura S, Sunazuka T, Greenblatt DJ, Zeng L. Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. Biochem Pharmacol. 2019;165:79–90.
41. Bowles RD, Mata BA, Bell RD, Mwangi TK, Huebner JL, Kraus VB, Setton LA. In vivo luminescence imaging of NF-κB activity and serum cytokine levels predict pain sensitivities in a rodent model of osteoarthritis. Arthritis Rheumatol. 2014;66:637–46.

42. Yamada EF, Salgueiro AF, Goulart AS, Mendes VP, Anjos BL, Folmer V, Silva MD. Evaluation of monosodium iodoacetate dosage to induce knee osteoarthritis: Relation with oxidative stress and pain. Int J Rheum Dis. 2019;22:399–410.

43. Teng P, Liu Y, Dai Y, Zhang HJ, Liu WT, Hu J. Nicotine Attenuates Osteoarthritis Pain and Matrix Metalloproteinase-9 Expression via the α7 Nicotinic Acetylcholine Receptor. J Immunol. 2019 Jul;15(2):485–92. 203(.

44. Shetty YC, Patil AE, Jalgaonkar SV, Rege NN, Salgaonkar S, Teltumbde PA, Kshirsagar S, Paresh Koli G, Brahma S. Intra-articular injections of ketamine and 25% dextrose improve clinical and pathological outcomes in the monosodium iodoacetate model of osteoarthritis. J Basic Clin Physiol Pharmacol. 2017;28:543–53.

45. Guingamp C, Pottie PG, Philippe L, Terlain B, Netter P, Gillet P. Mono-iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology, and biochemistry. Arthritis Rheum. 1997;40:1670–9.

46. Pritzker KPH, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, Salter D, Berg WB. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage. 2006;14:13–29.

47. Ivanavicius SP, Ball AD, Heapy CG, Westwood RF, Murray F, Read SJ. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: increased expression of ATF-3 and pharmacological characterisation. Pain. 2007;128:272–82.

48. Chung MF, Chia WT, Wan WL, Lin YJ, Sung HW. Controlled Release of an Anti-inflammatory Drug Using an Ultrasensitive ROS-Responsive Gas-Generating Carrier for Localized Inflammation Inhibition. J Am Chem Soc. 2015;137:12462–5.

49. Kaliamurthi S, Korkmaz AD, Selvaraj G, Polat EG, Wei YK, Almessiere MA, Baykal A, Gu K, Wei DQ. Viewing the Emphasis on State-of-the-Art Magnetic Nanoparticles: Synthesis, Physical Properties, and Applications in Cancer Theranostics. Curr Pharm Des. 2019;25:1505–23.

50. Wan SS, Cheng Q, Zeng X, Zhang XZ. A Mn(III)-Sealed Metal-Organic Framework Nanosystem for Redox-Unlocked Tumor Theranostics. ACS Nano. 2019;13:6561–71.

51. Dai YD, Sun XY, Sun W, Yang JB, Liu R, Luo Y, Zhang T, Tian Y, Lu ZL, He L. H2O2-responsive polymeric micelles with a benzil moiety for efficient DOX delivery and AIE imaging. Org Biomol Chem. 2019;17:5570–7.

52. Wilson DS, Dalmasso G, Wang LX, Sitaraman SV, Merlin D, Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater. 2010;9:923–8.

53. Chen DQ, Zhang GQ, Li RM, Guan MR, Wang XY, Zou TJ, Zhang Y, Wang CR, Shu CY, Hong H, Wan LJ. Biodegradable, Hydrogen Peroxide, and Glutathione Dual Responsive Nanoparticles for Potential Programmable Paclitaxel Release. J Am Chem Soc. 2018;140:7373–6.
54. Kwon EJ, Lasiene J, Jacobson BE, Park IK, Horner PJ, Pun SH. Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone. Biomaterials. 2010;31:2417–24.

55. Chen YP, Shen YY, Guo X, Zhang CS, Yang WJ, Ma ML, Liu S, Zhang MB, Wen LP. Transdermal protein delivery by a coadministered peptide identified via phage display. Nat Biotechnol. 2006;24:455–60.

**Tables**

Table 1 is not available with this version

**Figures**

Figure 1

Characterization of the functionalized TKC-PEG and TKC@DEX. TEM images of TKC-PEG (a) and TKC@DEX (b) NPs. Scale bar: 200 nm. (c) DLS characterization of TKC-PEG and TKC@DEX NPs. (d) The zeta potential of TKC-PEG and TKC@DEX NPs. (e) UV–vis absorption spectra of Cy5.5, BHQ-3 and TKC-
PEG NPs. Fluorescence intensity (f) and Relative fluorescence intensity (g) of TKC-PEG in different concentrations of KO2 (0 μM, 50 μM and 100 μM) or ROS inhibitor (NAC) for different times. Ex/Em of Cy5.5: 675/695 nm. (h) Size change of the TKC-PEG NPs incubated in pH 7.4 PBS buffer containing KO2 (0, 50 and 100 μM) or with ROS inhibitor (NAC) for different times. (i) Cumulative DEX release from the TKC@DEX NPs after incubation in PBS containing different concentrations of KO2 (0 μM, 50 μM and 100 μM) or with ROS inhibitor (NAC) for different times at 37 °C. (n = 3, mean ± SD).

Figure 2
In vitro cellular evaluation. Cell cytotoxicity of TKC-PEG against chondrocytes (a) and the effect of TKC@DEX on chondrocytes (b) determined by the CCK-8 assay after incubation for 24 or 48 h. (c) Cell viability of MIA-induced chondrocytes pretreated with culture medium only, DEX, CAP@DEX, TK@DEX or TKC@DEX for 24 h. (d) The hemolysis ratio of TKC@DEX at different concentrations. (e) The cellular uptake of TKC-PEG, TK-PEG or CAP-PEG NPs in normal chondrocytes, MIA-induced OA chondrocytes and in the presence of ROS inhibitor (NAC) OA chondrocytes for 24 h. The nuclei were counterstained with DAPI (blue). (f) Quantification of fluorescence after incubation with TKC-PEG for different concentrations of MIA (3 μM and 6 μM) or with ROS inhibitor (NAC) for 24 h. (g) Quantification of fluorescence after incubation with TKC-PEG, TK-PEG or CAP-PEG NPs in the presence of MIA (3 μM) for 24 h. Flow cytometry analysis (h) the production of intracellular ROS in chondrocytes at different concentrations of MIA (3 μM and 6 μM) or with ROS inhibitor (NAC) after incubation for 24 h. Scale bars: 100 μm. (n = 3; mean ± SD; *, # indicate p < 0.05; **, ## indicate p < 0.01; ***, ### indicate p < 0.001.)

Figure 3
Inhibiting the action of proinflammatory factors induced by MIA, as well as protecting the chondrocytes after incubation with DEX, TK@DEX, CAP@DEX or TKC@DEX. (a) Relative mRNA levels of MMP-13, IL-6, MMP-3 and Col2a1 on MIA-stimulated chondrocytes after incubation with DEX, CAP@DEX, TK@DEX or TKC@DEX. (b) Immunofluorescence images of MIA-stimulated chondrocytes after incubation with DEX, CAP@DEX, TK@DEX or TKC@DEX. (c) Quantifying the level of MMP-13 and IL-6 after treating with DEX, CAP@DEX, TK@DEX or TKC@DEX for 24 h. Scale bar: 200 μm. (n = 3; mean ± SD; *,# indicate p < 0.05; **, ## indicate p < 0.01, ***; ### indicate p < 0.001.)
Figure 4

In vivo fluorescent image after IA injection of CAP-PEG, TK-PEG or TKC-PEG probes to detect the level of ROS induced by MIA in C57BL6/J knees. (a) The up-regulated ROS activity in the OA joints was reflected by fluorescent signal and measured by an in vivo imaging system at selected time points after IA-injection. Ex: 630 nm, Em: 700 nm. (b) The relative fluorescence intensity of TKC-PEG, CAP-PEG or TK-PEG probes at different treatment times. (c) Representative photographs showed the macroscopic appearance of the cartilage from the femoral condyles and in vivo NIR bioimaging indicated the level of ROS via the fluorescent intensity according to the development of OA. Analysis of the macroscopic score (d) and relative fluorescent intensity (e) to evaluate the severity of OA. (n = 6; mean ± SD; *, # indicate p < 0.05, **; ## indicate p < 0.01; ***, #### indicate p<0.001.).

![Figure 4](image)

Figure 5

Macroscopic appearance and scoring of cartilage femoral condyles after treatment for 2 and 4 weeks. (a) The macroscopic observation and (b) the macroscopic scores of cartilages after IA-injection with PBS, DEX, CAP@DEX, TK@DEX or TKC@DEX (n=6; mean ± SD).

![Figure 5](image)

Figure 6

Histological evaluations of cartilage femoral condyles after IA injection of probes for 2 weeks and 4 weeks. H&E (a) and safranin-O/fast green (b) staining of cartilage sections. Scale bar: 400 μm. (c) Histological scoring of articular cartilage. (d) Immunohistochemical staining of MMP-13 was evaluated.
on cartilage sections after IA-injection with PBS, DEX, CAP@DEX, TK@DEX or TKC@DEX. Scale bar: 200 μm. (n = 6; mean ± SD; *, # indicate p < 0.05, **; ## indicate p < 0.01; ***, ### indicate p<0.001.)

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- Graphicalabstract.docx
- Suportinginformation.docx
- Scheme1.png